Similar articles

• Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.

  Welborn TA. Welborn TA. Med J Aust. 1998 Jan 19;168(2):76-8. Med J Aust. 1998. PMID: 9469188 Review. No abstract available.
• Clinical experience with acarbose as first line therapy in NIDDM.

  Fölsch UR. Fölsch UR. Clin Invest Med. 1995 Aug;18(4):312-7. Clin Invest Med. 1995. PMID: 8549018 Review.
• [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].

  Fölsch UR, Lembcke B. Fölsch UR, et al. Internist (Berl). 1991 Dec;32(12):699-707. Internist (Berl). 1991. PMID: 1823561 Review. German. No abstract available.
• [New, in Austria registered specialty drugs. Glucobay (acarbose)].

  Sturm M. Sturm M. Wien Klin Wochenschr. 1992;104(11):329-36. Wien Klin Wochenschr. 1992. PMID: 1621396 German. No abstract available.
• Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.

  Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ, Calle JR, Maranes JP. Calle-Pascual A, et al. Diabetes Metab. 1996 Jun;22(3):201-2. Diabetes Metab. 1996. PMID: 8697309 Clinical Trial. No abstract available.